We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Novartis (NVS - Free Report) will report quarterly earnings of $2.25 per share in its upcoming release, pointing to no change from the year-ago quarter. It is anticipated that revenues will amount to $14.56 billion, exhibiting an increase of 4.6% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Novartis metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Revenues- Oncology- Tafinlar + Mekinist- Total' to reach $531.43 million. The estimate suggests a change of -3.4% year over year.
The combined assessment of analysts suggests that 'Revenues- Other revenues' will likely reach $527.95 million. The estimate suggests a change of +17.6% year over year.
The average prediction of analysts places 'Revenues- Oncology- Kisqali- Total' at $1.85 billion. The estimate indicates a change of +39.5% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Immunology- Cosentyx- Total' should come in at $1.78 billion. The estimate suggests a change of +4.9% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tasigna- US' of $24.11 million. The estimate indicates a change of -69.5% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net sales- Oncology- Scemblix- ROW' should arrive at $204.53 million. The estimate indicates a change of +63.6% from the prior-year quarter.
Analysts expect 'Revenues- Oncology- Promacta/Revolade- US' to come in at $31.74 million. The estimate points to a change of -63.9% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Immunology- Cosentyx- US' will reach $1.05 billion. The estimate indicates a year-over-year change of +4%.
The consensus estimate for 'Revenues- Cardiovascular- Entresto- US' stands at $30.58 million. The estimate indicates a year-over-year change of -96.2%.
Analysts predict that the 'Revenues- Oncology- Tafinlar + Mekinist- US' will reach $186.73 million. The estimate indicates a change of -19.5% from the prior-year quarter.
Analysts' assessment points toward 'Net sales- Oncology- Scemblix- US' reaching $391.93 million. The estimate indicates a change of +68.2% from the prior-year quarter.
It is projected by analysts that the 'Net sales- Cardiovascular, renal and metabolic- Leqvio- ROW' will reach $286.98 million. The estimate indicates a change of +77.2% from the prior-year quarter.
Novartis shares have witnessed a change of +7.9% in the past month, in contrast to the Zacks S&P 500 composite's no move. With a Zacks Rank #3 (Hold), NVS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
Wall Street analysts forecast that Novartis (NVS - Free Report) will report quarterly earnings of $2.25 per share in its upcoming release, pointing to no change from the year-ago quarter. It is anticipated that revenues will amount to $14.56 billion, exhibiting an increase of 4.6% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Novartis metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Revenues- Oncology- Tafinlar + Mekinist- Total' to reach $531.43 million. The estimate suggests a change of -3.4% year over year.
The combined assessment of analysts suggests that 'Revenues- Other revenues' will likely reach $527.95 million. The estimate suggests a change of +17.6% year over year.
The average prediction of analysts places 'Revenues- Oncology- Kisqali- Total' at $1.85 billion. The estimate indicates a change of +39.5% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Immunology- Cosentyx- Total' should come in at $1.78 billion. The estimate suggests a change of +4.9% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tasigna- US' of $24.11 million. The estimate indicates a change of -69.5% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net sales- Oncology- Scemblix- ROW' should arrive at $204.53 million. The estimate indicates a change of +63.6% from the prior-year quarter.
Analysts expect 'Revenues- Oncology- Promacta/Revolade- US' to come in at $31.74 million. The estimate points to a change of -63.9% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Immunology- Cosentyx- US' will reach $1.05 billion. The estimate indicates a year-over-year change of +4%.
The consensus estimate for 'Revenues- Cardiovascular- Entresto- US' stands at $30.58 million. The estimate indicates a year-over-year change of -96.2%.
Analysts predict that the 'Revenues- Oncology- Tafinlar + Mekinist- US' will reach $186.73 million. The estimate indicates a change of -19.5% from the prior-year quarter.
Analysts' assessment points toward 'Net sales- Oncology- Scemblix- US' reaching $391.93 million. The estimate indicates a change of +68.2% from the prior-year quarter.
It is projected by analysts that the 'Net sales- Cardiovascular, renal and metabolic- Leqvio- ROW' will reach $286.98 million. The estimate indicates a change of +77.2% from the prior-year quarter.
View all Key Company Metrics for Novartis here>>>Novartis shares have witnessed a change of +7.9% in the past month, in contrast to the Zacks S&P 500 composite's no move. With a Zacks Rank #3 (Hold), NVS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .